Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

ABSTRACT: Major progress has been made toward our understanding of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway (referred to as the PD pathway). mAbs are already being used to block the PD pathway to treat human cancers (anti-PD therapy), especially advanced solid tumors. This therapy is based on principles that were discovered through basic research more than a decade ago, but the great potential of this pathway to treat a broad spectrum of advanced human cancers is just now becoming apparent. In this Review, we will briefly review the history and development of anti-PD therapy, from the original benchwork to the most up-to-date clinical results. We will then focus the discussion on three basic principles that define this unique therapeutic approach and highlight how anti-P

SUBMITTER: Chen L 

PROVIDER: S-EPMC4588282 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature